Freenome secures FDA nod for blood-based colorectal cancer test

Freenome has received FDA clearance for SimpleScreen, a blood-based colorectal cancer screening test that Abbott will distribute in the U.S. The test competes directly with Guardant Health's Shield blood test in the emerging non-invasive CRC screening market.

This Wire brief sits within Fusion42's coverage of Diagnostics. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.